Zhang Quan, Xu Lei, Wang Jianjun, Zhu Xiaoming, Ma Zeheng, Yang Junfeng, Li Jiwei, Jia Xiangbo, Wei Li
Department of Thoracic Surgery, Zhengzhou Key Laboratory of Surgical Treatment for End-Stage Lung Diseases, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, 450003, Henan, People's Republic of China.
Onco Targets Ther. 2021 Feb 22;14:1187-1204. doi: 10.2147/OTT.S288799. eCollection 2021.
KDM5C, a histone H3K4-specific demethylase, possess various biological functions in development of cancers. However, its relation to the microRNA (miRNA) regulation in lung cancer remains unknown. This study aims to study the regulatory role of KDM5C on modification of miR-133a in the progression of lung cancer.
Differentially expressed miRNAs were filtered from 34 paired lung cancer and paracancerous tissues. The correlation between miR-133a expression and the prognosis of lung cancer patients was determined by a bioinformatics website. Furthermore, malignant aggressiveness of lung cancer cells was detected after miR-133a upregulation by CCK-8, flow cytometry, and Transwell assays and in vivo tumorigenesis and metastasis experiments. Subsequently, we analyzed mRNA downregulated in cells overexpressing miR-133a using m microarray analysis and expounded the upstream regulatory mechanism of miR-133a using bioinformatics website prediction and functional validation.
miR-133a was reduced in lung cancer tissues, and patients with low expression of miR-133a have worse survival rates. miR-133a restoration curtailed growth and metastasis of lung cancer cells in vitro and in vivo. Moreover, miR-133a downregulated PTBP1 expression, whereas overexpression of PTBP1 attenuated the suppressive effect of miR-133a on lung cancer cell aggressiveness. The level of methylation modification of miR-133a was reduced in lung cancer cells. KDM5C inhibited the expression of miR-133a by promoting the demethylation modification of its promoter histone.
Histone demethylase KDM5C inhibits the expression of miR-133a by elevating the demethylation modification of the promoter histone of miR-133a, thereby promoting the expression of PTBP1, which finally accelerates lung cancer cell growth and metastasis.
KDM5C是一种组蛋白H3K4特异性去甲基化酶,在癌症发展过程中具有多种生物学功能。然而,其与肺癌中微小RNA(miRNA)调控的关系尚不清楚。本研究旨在探讨KDM5C在肺癌进展中对miR-133a修饰的调控作用。
从34对肺癌组织和癌旁组织中筛选差异表达的miRNA。通过生物信息学网站确定miR-133a表达与肺癌患者预后的相关性。此外,通过CCK-8、流式细胞术和Transwell实验以及体内肿瘤发生和转移实验,检测miR-133a上调后肺癌细胞的恶性侵袭性。随后,我们使用基因芯片分析了过表达miR-133a的细胞中下调的mRNA,并通过生物信息学网站预测和功能验证阐述了miR-133a的上游调控机制。
miR-133a在肺癌组织中表达降低,miR-133a低表达的患者生存率较差。miR-133a的恢复抑制了肺癌细胞在体外和体内的生长和转移。此外,miR-133a下调PTBP1表达,而PTBP1的过表达减弱了miR-133a对肺癌细胞侵袭性的抑制作用。肺癌细胞中miR-133a的甲基化修饰水平降低。KDM5C通过促进其启动子组蛋白的去甲基化修饰来抑制miR-133a的表达。
组蛋白去甲基化酶KDM5C通过提高miR-133a启动子组蛋白的去甲基化修饰来抑制miR-133a的表达,从而促进PTBP1的表达,最终加速肺癌细胞的生长和转移。